Back to News & Events

Traverse Biosciences Executes Exclusive, Worldwide License Agreement

Traverse Biosciences, founded by Joseph Scaduto – one of the Center for Biotechnology’s first BioEntrepreneurs-in-Residence, announced today that it has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY) for access to the animal health applications of a proprietary library of polyenolic zinc-binding agents. The license agreement also extends Traverse Biosciences the exclusive option to license the human health applications of these promising drug candidates.

The drug compounds were invented by Lorne Golub, DMD, MD (Honorary), Distinguished Professor in the Department of Oral Biology and Pathology in the Stony Brook University School of Dental Medicine, and Francis Johnson, PhD, President of Chem-Master International Inc. and Professor of Chemistry and Pharmacology at Stony Brook. The drugs were developed in concert with the the Center for Biotechnology at Stony Brook University. The Center provided financial support to help the inventors develop their lead compound and for follow-on animal studies.

Click to read the press releases from Stony Brook University and Traverse Biosciences.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2706 [post_author] => 3 [post_date] => 2017-06-02 14:04:51 [post_date_gmt] => 2017-06-02 14:04:51 [post_content] => Dr. Sasha Levy, Marsha Laufer Endowed Assistant Professor of Physical and Quantitative Biology for the Laufer Center and the Department of Biochemistry & Cell Biology at Stony Brook University, recently had an article published in Nature Communications related to his research supported by the Long Island Bioscience Hub. In the article, Dr. Levy’s group has described a next-generation high-throughput system for studying protein-protein interactions in yeast, without the limitations of previous techniques, by monitoring relative barcode frequencies across time periods. This allows large scale study of protein interaction changes across dynamic environments, and can be used for rapid drug screening assays. Access the article here. [post_title] => LIBH Researcher Published in Nature Communications [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => libh-researcher-published-in-nature-communications [to_ping] => [pinged] => [post_modified] => 2017-06-02 14:04:51 [post_modified_gmt] => 2017-06-02 14:04:51 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2706 [menu_order] => 144 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3107 [post_author] => 3 [post_date] => 2018-12-18 16:28:18 [post_date_gmt] => 2018-12-18 16:28:18 [post_content] => The Center for Biotechnology will be hosting our annual SBIR/STTR NIH Focused Workshop on January 15-16, 2019. Did you know that the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) SBIR/STTR programs award over $2.6 billion in high-risk, non-diluted R&D funding annually to qualified small businesses? Learn more about SBIR/STTR funding at this 1.5-day session focused on the National Institutes of Health (NIH) which will cover program essentials and how to compete for funding. Training will include: – Current information on the SBIR/STTR programs – Strategies for targeting your proposal to address the mission and requirements of the NIH – How to approach each section of your proposal – Planning your commercialization strategy – Writing to meet the reviewers’ expectations Tuesday, January 15, 2019, 8:30am – 4:30pm Wednesday, January 17, 2019, 8:30am –12:00pm Location: Long Island High Technology Incubator Main Conference Room 25 Health Sciences Drive Stony Brook, NY 11794 Registration Fee: $60 | Space is Limited. Pre-registration is required. REGISTER ONLINE [post_title] => SBIR/STTR INTENSIVE WORKSHOP: NIH FOCUSED [post_excerpt] => The Center for Biotechnology will be hosting our annual SBIR/STTR NIH Focused Workshop on January 15-16, 2019. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbirsttr-intensive-workshop-nih-focused [to_ping] => [pinged] => [post_modified] => 2019-01-24 15:35:16 [post_modified_gmt] => 2019-01-24 15:35:16 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3107 [menu_order] => 107 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3181 [post_author] => 3 [post_date] => 2019-02-28 16:35:02 [post_date_gmt] => 2019-02-28 16:35:02 [post_content] => Center for Biotechnology Director Dr. Clinton Rubin has co-authored a recent article published in Nature Reviews Endocrinology "“Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity”.  Abstract below, full article here. Abstract:  Osteoporosis, a condition of skeletal decline that undermines quality of life, is treated with pharmacological interventions that are associated with poor adherence and adverse effects. Complicating efforts to improve clinical outcomes, the incidence of obesity is increasing, predisposing the population to a range of musculoskeletal complications and metabolic disorders. Pharmacological management of obesity has yet to deliver notable reductions in weight and debilitating complications are rarely avoided. By contrast, exercise shows promise as a non-invasive and non-pharmacological method of regulating both osteoporosis and obesity. The principal components of exercise — mechanical signals — promote bone and muscle anabolism while limiting formation and expansion of fat mass. Mechanical regulation of bone and marrow fat might be achieved by regulating functions of differentiated cells in the skeletal tissue while biasing lineage selection of their common progenitors — mesenchymal stem cells. An inverse relationship between adipocyte versus osteoblast fate selection from stem cells is implicated in clinical conditions such as childhood obesity and increased marrow adiposity in type 2 diabetes mellitus, as well as contributing to skeletal frailty. Understanding how exercise-induced mechanical signals can be used to improve bone quality while decreasing fat mass and metabolic dysfunction should lead to new strategies to treat chronic diseases such as osteoporosis and obesity. [post_title] => “Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity” [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => combating-osteoporosis-and-obesity-with-exercise-leveraging-cell-mechanosensitivity [to_ping] => [pinged] => [post_modified] => 2019-04-09 14:40:26 [post_modified_gmt] => 2019-04-09 14:40:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3181 [menu_order] => 100 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

LIBH Researcher Published in Nature Communications

More Information

SBIR/STTR INTENSIVE WORKSHOP: NIH FOCUSED

More Information

“Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity”

More Information